Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathies

Arthritis and Rheumatology

Volumn 66, Issue 4, 2014, Pages 1022-1033

  Georgantas, Robert W ^a   Streicher, Katie ^a   Greenberg, Steven A ^b   Greenlees, Lydia M ^a   Zhu, Wei ^a   Brohawn, Philip Z ^a   Higgs, Brandon W ^a   Czapiga, Meggan ^a   Morehouse, Christopher A ^a   Amato, Anthony ^b   Richman, Laura ^a   Jallal, Bahija ^a   Yao, Yihong ^a   Ranade, Koustubh ^a  

^a MEDIMMUNE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 8; MICRORNA; MICRORNA 1; MICRORNA 133; MICRORNA 133A; MICRORNA 133B; MICRORNA 206; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCLUSION BODY MYOSITIS; INFLAMMATION; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MYOBLAST; MYOSITIS; MYOTUBE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; MICRORNAS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOSITIS; NF-KAPPA B;

EID: 84898657573     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38292     Document Type: Article

References (38)

1. Miller FW,. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71 Suppl 2: i82-5.
2. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC,. Update on idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 161-70.
3. Dorph C, Lundberg IE,. Idiopathic inflammatory myopathies: myositis. Best Pract Res Clin Rheumatol 2002; 16: 817-32.
4. Dalakas MC,. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98.
5. Greenberg SA,. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12: 221-8.
6. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia: Elsevier; 2011.
7. Oddis CV,. Idiopathic inflammatory myopathy: management and prognosis. Rheum Dis Clin North Am 2002; 28: 979-1001.
8. Engel AG, Arahata K,. Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15.
9. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL,. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35: 17-23.
10. Grundtman C, Malmstrom V, Lundberg IE,. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther 2007; 9: 208.
11. Greenberg SA,. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69: 2008-19.
12. Hilton-Jones D,. Inflammatory muscle diseases. Curr Opin Neurol 2001; 14: 591-6.
13. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
14. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD,. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839-45.
15. Sonkoly E, Stahle M, Pivarcsi A,. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18: 131-40.
16. Van Rooij E, Liu N, Olson EN,. MicroRNAs flex their muscles. Trends Genet 2008; 24: 159-66.
17. Boutz PL, Chawla G, Stoilov P, Black DL,. MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev 2007; 21: 71-84.
18. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38: 228-33.
19. Anderson C, Catoe H, Werner R,. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res 2006; 34: 5863-71.
20. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, et al. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 2007; 104: 20844-9.
21. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF,. Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci U S A 2006; 103: 8721-6.
22. Gagan J, Dey BK, Dutta A,. MicroRNAs regulate and provide robustness to the myogenic transcriptional network. Curr Opin Pharmacol 2012; 12: 383-8.
23. O'Connell RM, Rao DS, Baltimore D,. microRNA regulation of inflammatory responses. Ann Rev Immunol 2012; 30: 295-312.
24. Contreras J, Rao DS,. MicroRNAs in inflammation and immune responses. Leukemia 2012; 26: 404-13.
25. Kuang W, Tan J, Duan Y, Duan J, Wang W, Jin F, et al. Cyclic stretch induced miR-146a upregulation delays C2C12 myogenic differentiation through inhibition of Numb. Biochem Biophys Res Commun 2009; 378: 259-63.
26. Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F, et al. MicroRNA-221 and microRNA-222 modulate differentiation and maturation of skeletal muscle cells. PloS One 2009; 4: e7607.
27. Gagan J, Dey BK, Layer R, Yan Z, Dutta A,. MicroRNA-378 targets the myogenic repressor MyoR during myoblast differentiation. J Biol Chem 2011; 286: 19431-8.
28. Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F, Falcieri E,. C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur J Histochem 2004; 48: 223-33.
29. Yaffe D, Saxel O,. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977; 270: 725-7.
30. Miller JB,. Myogenic programs of mouse muscle cell lines: expression of myosin heavy chain isoforms, MyoD1, and myogenin. J Cell Biol 1990; 111: 1149-59.
31. Aggarwal BB,. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-56.
32. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr,. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289: 2363-6.
33. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J,. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995; 270: 14255-8.
34. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A,. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007; 21: 1857-69.
35. Panguluri SK, Bhatnagar S, Kumar A, McCarthy JJ, Srivastava AK, Cooper NG, et al. Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PloS One 2010; 5: e8760.
36. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, et al. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A 2007; 104: 17016-21.
37. Hayden MS, Ghosh S,. Signaling to NF-κB. Genes Devel 2004; 18: 2195-224.
38. Marie I, Mouthon L,. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011; 11: 6-13.